

VESSEL QUALITY ASSURANCE POLICY

1.0 Purpose

NLNG Shipping and Marine Services Ltd is committed to ensuring that Fleet vessels are effectively and safely managed. It is a commitment which is in the best interest of our employees, the environment, our customers, our shareholders and our reputation at large. Every managed vessel is vetted by oil majors under OCIMF SIRE Scheme, owner's and charterer during the course of operations.

1.1 Policy Objective

The following objectives underline the NSML Vessel Quality Assurance Policy to avoid NSML being associated with a sub-standard vessel, hence to:

- Avoid harm to people
- Avoid harm to the environment
- Protect the Company's Assets
- Avoid harm to the Company's reputation

To provide assurance to our customers and stakeholders that the risk associated with fleet vessels is effectively managed and reduced to As Low As Reasonably Practicable (ALARP).

1.2 Scope and Application

The content of this Policy shall apply to all vessels managed by NSML.

In pursuit of this Policy, NSML Shall:

1. Positively ensure that all managed vessels are vetted by Oil majors under the OCIMF SIRE Scheme every six months.
2. Carry out internal/external audits of managed vessels through completing vessel's class survey, ISM/ISPS/ISO 9001/ISO 14001 and MLC 2006 accreditation, other flag state certification and management reviews.
3. Underpin its Integrated Management System (IMS) with clear objectives and key performance indicators.
4. Maintain close liaison with vessel owner, charterer, Government and Industry bodies as well as other stakeholders.
5. Ensure that employees are made aware of the Vessel Quality Assurance process.

1.3 Implementation

There are a number of approved "Procedures and Guidelines" which collectively demonstrate the achievement of this policy. They provide adequate details to effectively manage NSML's Ship Management risks. Compliance will be verified at all levels of the business by a monitoring and audit programme that ensures effective implementation of the process.



ABDULKADIR K. AHMED

MD/CEO

January, 2024.